Advanced Magnetics reports positive data in Phase III

Cambridge, MA-based Advanced Magnetics is touting positive results from its late-stage therapy for chronic kidney disease. The Phase III trial for the intravenous iron replacement therapy hit primary and secondary endpoints. Patients taking ferumoxytol who were not dependent on dialysis demonstrated a significant increase in hemoglobin. The trial results are being released today at the American Society of Nephrology's Renal Week in San Diego. Advanced Magnetics says that it's on track to submit an NDA in the second half of 2007.

- here's the release on the trial data

Suggested Articles

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.